stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) Gross margin
Harmony Biosciences Holdings, Inc.'s gross margin over the twelve months to 30 September 2026 was 74.0%, down 3.1 percentage points from fiscal 2025 (77.2%). Over the past ten years it has ranged from 0.00% (fiscal 2018) to 82.6% (fiscal 2020); the current reading is higher than 38% of that period. That is above the Biotechnology industry median of 68.5% and above the Healthcare sector median of 54.5%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 77.2% | (0.90) |
| FY2024 | 78.1% | (1.11) |
| FY2023 | 79.2% | (1.76) |
| FY2022 | 80.9% | (0.89) |
| FY2021 | 81.8% | (0.82) |
| FY2020 | 82.6% | 8.95 |
| FY2019 | 73.7% | 73.69 |
| FY2018 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 70.0% | (5.81) |
| Jun 2026 | 75.8% | (3.52) |
| Mar 2026 | 79.3% | 7.45 |
| Dec 2025 | 71.9% | (3.21) |
| 24 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| VIR Vir Biotechnology, Inc. compare | 100.0% |
| HRMY Harmony Biosciences Holdings, Inc. | 74.0% |
| FTRE Fortrea Holdings Inc. compare | 20.0% |
| SRPT Sarepta Therapeutics, Inc. compare | 0.00% |
| REPL Replimune Group, Inc. compare | 0.00% |
| TRVI Trevi Therapeutics, Inc. compare | 0.00% |
| MESO Mesoblast Limited compare | −269.7% |
| MAZE Maze Therapeutics, Inc. compare | — |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
| Biotechnology industry median | 68.5% |
| Healthcare sector median | 54.5% |
| Market median | 46.0% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue